Should prolactin be reconsidered as a therapeutic target in human breast cancer?

Molecular and Cellular Endocrinology

Volumn 151, Issue 1-2, 1999, Pages 79-87

  Goffin, Vincent ^a   Touraine, Philippe ^a   Pichard, Caroline ^a   Bernichtein, Sophie ^a   Kelly, Paul A ^a  

^a INSERM   (France)

Author keywords

16K prolactin; Angiogenesis; Antagonist; Breast cancer; Prolactin; Prolactin receptor

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; PROLACTIN RECEPTOR; SOMATOSTATIN;

ANGIOGENESIS; BREAST CANCER; CANCER RISK; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033603020     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00023-4     Document Type: Article

References (71)

1. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:1995;27489-27494.
2. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., Carter-Su C. Identification of Jak2 as a growth hormone receptor-associated tyrosine kinase. Cell. 74:1993;237-244.
3. Ben-Jonathan N., Mershon J.L., Allen D.L., Steinmetz R.W. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev. 17:1996;639-669.
4. Berwaer M., Martial J.A., Davis J.R. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Mol. Endocrinol. 8:1994;635-642.
5. Bole-Feysot C., Goffin V., Edery M., Binart N., Kelly P.A. Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr. Rev. 19:1998;225-268.
6. Boutin J.M., Jolicoeur C., Okamura H., Gagnon J., Edery M., Shirota M., Banville D., Dusanter-Fourt I., Djiane J., Kelly P.A. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell. 53:1988;69-77.
7. Chen W.Y., Chen N.Y., Yun J., Wagner T.E., Kopchick J.J. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J. Biol. Chem. 269:1994;15892-15897.
8. Chen T.J., Kuo C.B., Tsai K.F., Liu J.W., Chen D.Y., Walker A.M. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology. 139:1998;609-616.
9. Clapp C., Weiner R.I. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology. 130:1992;1380-1386.
10. Clapp C., Martial J.A., Guzman R.C., Rentier-Delrue F., Weiner R.I. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 133:1993;1292-1299.
11. Clevenger C.V., Chang W.P., Ngo W., Pasha T.M., Montone K.T., Tomaszewski J.E. Expression of prolactin and prolactin receptor in human breast carcinoma. Am. J. Pathol. 146:1995;695-705.
12. Clevenger C.V., Plank T.L. Prolactin as an autocrine/paracrine factor in breast cancer. J. Mamm. Gland. Biol. Neopl. 2:1997;59-68.
13. D'Angelo G., Struman I., Martial J.A., Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblasts growth factor in capillary endothelial cells is inhibited by the anti-angiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA. 92:1995;6374-6378.
14. Darnell J.E. STATs and gene regulation. Science. 277:1997;1630-1635.
15. Das R., Vonderhaar B.K. Activation of raf-1 MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res. Treat. 40:1996a;141-149.
16. Das R., Vonderhaar B.K. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene. 13:1996b;1139-1145.
17. Das R., Vonderhaar B.K. Prolactin as a mitogen in mammary cells. J. Mamm. Gland. Biol. Neopl. 2:1997;29-39.
18. DaSilva L., Rui H., Erwin R.A., Zack H., Kirken R.A., Malabarba M.G., Hackett R.H., Larner A.C., Farrar W.L. Prolactin recruits STAT1 STAT3 and STAT5 independent of conserved receptor tyrosines TYR 402, TYR 476, TYR 515 and TYR 580. Mol. Cell. Endocrinol. 117:1996;131-140.
19. De Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 255:1992;306-312.
20. Delhase M., Vergani P., Malur A., Hooghe-Peters E.L., Hooghe R.J. The transcription factor Pit-1/GHF-1 is expressed in hemopoietic and lymphoid tissues. Eur. J. Immunol. 23:1993a;951-955.
21. Delhase M., Vergani P., Malur A., Velkeniers B., Teugels E., Trouillas J., Hooghe-Peters E.L. Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. J. Mol. Endocrinol. 11:1993b;129-139.
22. DiMattia G.E., Gellersen B., Duckworth M.L., Friesen H.G. Human prolactin gene expression. the use of an alternative non coding exon in decidua and the IM-9-P3 lymphoblast cell line. J. Biol. Chem. 265:1990;16412-16421.
23. Dufourny B., Alblas J., van Teeffelen H.A., van Schaik F.M., van der Burg B., Steenbergh P.H., Sussenbach J.S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J. Biol. Chem. 272:1997;31163-31171.
24. Ferrara N., Clapp C., Weiner R.I. The 16K fragment of rat prolactin specifically inhibits basal or FGF stimulated growth of capillary endothelial cells. Endocrinology. 129:1991;896-906.
25. Fuh G., Cunningham B.C., Fukunaga R., Nagata S., Goeddel D.V., Wells J.A. Rational design of potent antagonists to the human growth hormone receptor. Science. 256:1992;1677-1679.
26. Fuh G., Colosi P., Wood W.I., Wells J.A. Mechanism-based design of prolactin receptor antagonists. J. Biol. Chem. 268:1993;5376-5381.
27. Fuh G., Wells J.A. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol. Chem. 270:1995;13133-13137.
28. Gasparini G., Harris A.L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol. 13:1995;765-782.
29. Gellersen B., Kempf R., Telgmann R., DiMattia G.E. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol. Endocrinol. 8:1994;356-373.
30. Gimbrone M.A.J., Gullino P.M. Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J. Natl. Cancer Inst. 56:1976;305-318.
31. Ginsburg E., Vonderhaar B.K. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 55:1995;2591-2595.
32. Goffin V., Struman I., Mainfroid V., Kinet S., Martial J.A. Evidence for a second receptor binding site on human prolactin. J. Biol. Chem. 269:1994;32598-32606.
33. Goffin V., Kinet S., Ferrag F., Binart N., Martial J.A., Kelly P.A. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J. Biol. Chem. 271:1996a;16573-16579.
34. Goffin V., Shiverick K.T., Kelly P.A., Martial J.A. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr. Rev. 17:1996b;385-410.
35. Goffin V., Kelly P.A. The prolactin/growth hormone receptor family: structure/function relationships. J.Mamm. Gland. Biol. Neopl. 2:1997;7-17.
36. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
37. Harris J.R., Lippman M.E., Veronesi U., Willett W. Breast cancer (1). New Engl. J. Med. 327:1992;319-328.
38. Helman D., Staten N.R., Grosclaude J., Daniel N., Nespoulous C., Djiane J., Gertler A. Novel recombinant analogues of bovine placental lactogen: G133K and G133R provide a tool to understand the difference between the action of prolactin and growth hormone receptors. J. Biol. Chem. 273:1998;16067-16074.
39. Ihle J.N., Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11:1995;69-74.
40. Ilondo M.M., Damholt A.B., Cunningham B.C., Wells J.A., De Meyts P., Shymko R.M. Receptor dimerization determines the effect of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology. 134:1994;2397-2403.
41. Jackson J.G., White M.F., Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem. 273:1998;9994-10003.
42. King R.J. William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res. Treat. 27:1993;3-15.
43. Lebrun J.J., Ali S., Sofer L., Ullrich A., Kelly P.A. Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase. J. Biol. Chem. 269:1994;14021-14026.
44. Lebrun J.J., Ali S., Ullrich A., Kelly P.A. Proline-rich sequence-mediated JAK2 association to the prolactin receptor is required but not sufficient for signal transduction. J. Biol. Chem. 270:1995;10664-10670.
45. Lee H., Struman I., Clapp C., Martial J., Weiner R.I. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology. 139:1998;3696-3703.
46. Lichtenbeld H.C., Barendsz-Janson A.F., van Essen H., Struijker B.H., Griffioen A.W., Hillen H.F. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int. J. Cancer. 77:1998;455-459.
47. Lippman M.E., Dickson R.B., Bates S., Knabbe C., Huff K., Swain S., McManaway M., Bronzert D., Kasid A., Gelmann E.P. 8th San Antonio Breast Cancer Symposium - Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res. Treat. 7:1986;59-70.
48. Liu X., Robinson G.W., Wagner K.U., Garrett L., Wynshaw-Boris A., Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11:1997;179-186.
49. Livnah O., Stura E.A., Johnson D.L., Middleton S.A., Mulcahy L.S., Wrighton N.C., Dower W.J., Jolliffe L.K., Wilson I.A. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 273:1996;464-471.
50. Malarkey W.B., Kennedy M., Allred L.E., Milo G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J. Clin. Endocrinol. Metab. 56:1983;673-677.
51. Manni A., Boucher A.E., Demers L.M., Harvey H.A., Lipton A., Simmonds M.A., Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res.Treat. 14:1989;289-298.
52. Mershon J., Sall W., Mitchner N., Ben-Jonathan N. Prolactin is a local growth factor in rat mammary tumors. Endocrinology. 136:1995;3619-3623.
53. Mertani H.C., Garcia-Caballero T., Lambert A., Gerard F., Palayer C., Boutin J.M., Vonderhaar B.K., Waters M.J., Lobie P.E., Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer. 79:1998;202-211.
54. Meydan N., Grunberger T., Dadi H., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C.M. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature. 379:1996;645-648.
55. Nielsen M., Kaltoft K., Nordahl M., Ropke C., Geisler C., Mustelin T., Dobson P., Svejgaard A., Odum N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. USA. 94:1997;6764-6769.
56. Ormandy C.J., Camus A., Barra J., Damotte D., Lucas B.K., Buteau H., Edery M., Brousse N., Babinet C., Binart N., Kelly P.A. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11:1997;167-178.
57. Osherov N., Levitzki A. Tyrphostin AG 494 blocks Cdk2 activation. FEBS Lett. 410:1997;187-190.
58. Pellegrini I., Lebrun J.J., Ali S., Kelly P.A. Expression of prolactin and its receptor in human lymphoid cells. Mol. Endocrinol. 6:1992;1023-1031.
59. Pezet A., Buteau H., Kelly P.A., Edery M. The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. Mol. Cell. Endocrinol. 129:1997;199-208.
60. Pritchard K.I. Is tamoxifen effective in prevention of breast cancer? Lancet. 352:1998;80-81.
61. Reynolds C., Montone K.T., Powell C.M., Tomaszewski J.E., Clevenger C.V. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 138:1997;5555-5560.
62. Shaw-Bruha C.M., Pirrucello S.J., Shull J.D. Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Res. Treat. 44:1997;243-253.
63. Sinha Y.N. Structural variants of prolactin: occurence and physiological significance. Endocr. Rev. 16:1995;354-369.
64. Struman I., Bentzein F., Lee H., Mainfroid V., D'Angelo G., Goffin V., Weiner R.I., Martial J.A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: novel mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA. 96:1999;1246-1251.
65. Topper Y.J. Multiple hormone interactions in the development of mammary gland in vitro. Recent. Prog. Horm. Res. 26:1970;287-308.
66. Touraine P., Martini J.F., Zafrani B., Durand J.C., Labaille F., Malet C., Nicolas A., Trivin C., Postel-Vinay M.C., Kuttenn F., Kelly P.A. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 83:1998;667-674.
67. Udy G.B., Towers R.P., Snell R.G., Wilkins R.J., Park S.H., Ram P.A., Waxman D.J., Davey H.W. Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;7239-7244.
68. Vignon F., Bardon S., Chalbos D., Rochefort H. Antiestrogenic effect of R5020. a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56:1983;1124-1130.
69. Vonderhaar B.K. Prolactin: the forgotten hormone of human breast cancer. Pharmacol. Ther. 79:1998;169-178.
70. Wells J.A. Binding in the growth hormone receptor complex. Proc. Natl. Acad. Sci. USA. 93:1996;1-6.
71. Wennbo H., Gebre-Medhin M., Gritli-Linde A., Ohlsson C., Isaksson O.G., Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. 100:1997;2744-2751.